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The immune interactions occurring within the tumor microenvironment have a critical role in determining the outcome
of colorectal cancer patients. We carried-out an immunohistochemical analysis of tumor infiltrating T-lymphocytes
expressing chemokine receptor 7 (CCR7) in a series of colorectal cancer patients enrolled in a prospective clinical trial. We
demonstrated that a high tumor infiltration score of this lymphocyte subset is predictive of longer progression free
survival and overall survival.
Adaptive immunity is considered to play a
crucial role for a long survival of cancer
patients.1 Recent findings support the
idea that the immune microenvironment
of colorectal cancer has important peculi-
arities. In fact, primary tumor infiltration
by regulatory T cells expressing the FOXP3
transcription factor [CD4+ CD25+FoxP3+
T cells (Treg)], commonly considered as
immune-suppressive cells, represents an
unpredicted favorable prognostic value
both in local2 and in advanced disease.3
Although a clear explanation of this
finding is not currently available, several
hypotheses have been formulated. We
suggested that the presence of Treg is an
indirect sign of a preexisting and efficient
anti-tumor immune-response.3 In the
attempt to clarify this issue we decided
to investigate the prognostic value of
different tumor infiltrating T lymphocyte
subsets in a recent work.4 At this aim we
performed an immunohistochemical ana-
lysis to evaluate the prognostic value of
tumor infiltrating CD8+ T cells expres-
sing the chemokine-receptor-7 (Tccr7) and
the possible correlation between tumor
infiltration by Tccr7 and Treg. The study
involved 76 patients enrolled in a Phase
III trial on first line treatment for meta-
static colorectal cancer (mCRC), named
GOLFIG-2 trial, comparing GOLFIG
[Gemcitabine (1,000mg/m2 on days 1
and 15), oxaliplatin (85mg/m2 on days
2 and 16), LF (100 mg/m2 on days 1, 2,
15 and 16) and 5-FU (400mg/m2 as a
bolus and 800mg/m2 as a 24 h infusion
on days 1, 2, 15 and 16), followed by
subcutaneous rGM-CSF (100 mg, on days
3–7) and ultra-low dose subcutaneous
rIL-2 (0.5  106 IUs twice a day on days
8–14 and 17–29)] chemo immuno-
therapy5 vs FOLFOX-4 regimen.
High Tccr7 tumor infiltration was pre-
dictive of prolonged Overall Survival (OS)
[high vs. low Tccr7 score HR = 0.48 (95%
CI; 0.24–0.96); p = 0.03] and prolonged
Progression Free Survival (PFS) [high vs.
low Tccr7 score: HR = 0.54 (95% CI;
0.28–1.01); p = 0.01] after front-line
chemotherapy. Patients with high infiltra-
tion by both Tccr7 and Treg presented a
favorable outcome, while the outcome was
very poor for concomitant low Tccr7 and
Treg [HR = 0.32 (95% CI; 0.12–0.87);
p = 0.02 for OS HR = 0.43 (95% CI;
0.17–1.06) for PFS; p = 0.01]. These
findings led us to conclude that a high
Tccr7 tumor infiltration score has a favor-
able prognostic value for mCRC.4
How to interpret these findings in the
general scenario of colorectal cancer
microenvironment? CCR7 is a chemokine
receptor involved in chemotaxis, expressed
on naïve-T lymphocytes and on central
memory T lymphocytes. CCR7 ability to
bind chemokine ligand (CCL)-19 and
CCL-21 allows it to drive these different
lymphocyte subpopulations at the site of
the “immune-attack”: naïve-T lympho-
cytes may subsequently differentiate in
cytotoxic effectors or central memory;
whereas central memory T lymphocytes
may proliferate and differentiate in acti-
vated effector lymphocytes. Both these
events may lead to a tumor-specific
immune-response with potential anti-
tumor activity. On these basis, patients
with a high CCR7 tumor infiltration
probably have a still competent immune
system with effector arms in full action.
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Moreover, the presence of Treg may
represent an attempt to attenuate a
potentially dangerous over-reaction and
auto-immunity. In our series, we found
that Tccr7 and Treg co-infiltration in the
tumor tissue confers a survival advantage
but the coordinated expression of the two
lymphocyte population doesn’t occur in
most tumors. This suggests that other
points need to be considered in order to
explain the prognostic value of Treg.
Ladoire et al. have focused attention on
the unique colon tissue microbiological
environment, which in specific condition
may activate a Th-17-dependent inflam-
matory response, that in turn, exerts a
powerful immune-suppressive and tumor
promoting effect. In this view Treg act
as specific repressors of IL-17 induced
inflammation.6 Furthermore, myeloid
derived suppressor cells may be attracted
in tumor tissues by different inflamma-
tory cytokines, became tumor-associated
macrophages and tumor-associated neutro-
phils and, in turn, promote tumor progres-
sion by means of Th1-immunosuppressive
activity.7,8 Colorectal cancer microenviron-
ment appears therefore to modulate
tumor progression by counterbalancing
effects, inflammatory cytokines driven
tumor vs. Tccr7 and Treg anti-inflammatory
immune promoting activity (Fig. 1).
At this aim, our findings add novel
information demonstrating that tumor
infiltrating Tccr7 positively affect long-
term disease outcome and represent
therefore important actors in the
scenario of colorectal cancer immune
microenvironment.
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Figure 1. The figure is representative of the opposite function of different tumor infiltrating immune-cells. (A and B) explain the pro-tumor activity of
several infiltrating myeloid derived cells (such as neutrophils and macrophages) driven by a Th-17- mediated inflammation. This condition leads to the
suppression of the adaptive antitumor immune response and, consequently, to a low tumor infiltration by either CCR7+ and FoxP3+ lymphocytes
(double-low tumors). Conversely, (C and D) show a tumor highly infiltrated by both CCR7+ and FoxP3+ lymphocytes (double-high tumors). In this view,
FoxP3+ may act by regulating tumor-dependent inflammation thus enhancing a tumor-specific response, leading to an efficient antitumor activity
mediated by CCR7+ lymphocytes.
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